title: [Hodgkin disease, clinical stages IA-IIB: evaluation of the value of cisplatin. Preliminary results].
abstract: Cisplatinum is highly effective in numerous solid tumors and was evaluated in Hodgkin's disease clinical stages (CS) I/II. Sixty-five patients (43 male, 22 female; median age 25, with 12 patients under 16: CS IA-IIA 41, IB 5, IIB 19) were randomly assigned to one of the following arms (PAF87 protocol): 3 ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine with methylprednisolone) cycles (ABVD arm) or 3 ABVD plus cisplatinum cycles (ABVD-Plt arm) followed by radiotherapy (RT); extended field (40 Gy) RT with a short paraaortic field including the spleen (30 Gy) was then administered in the ABVD arm; extended field (30 Gy) without lombosplenic port prophylaxis. RT was administered in ABVD-Plt arm when patients were in complete remission (CR) after chemotherapy (CT). Median follow-up was 35 months (6-62 months). During CT, 1 patient (ABVD-Plt) died from viral meningo-encephalitis; five patients (1 ABVD, 4 ABVD-Plt) stopped treatment because of emesis, of whom three receiving only 1.5-2.5 (ABVD-Plt) cycles, are still in CR after 13-60 months. Fifty-five patients (27 ABVD-Plt) were in CR after CT. Among the 27 ABVD-Plt patients, all in CR after RT, two died (one from myocardial infarction and one from immunoblastic lymphoma); one patient from the ABVD arm died from gastro-intestinal hemorrhage in 1st CR. No ABVD-Plt patient relapsed; 1 ABVD patient relapsed in non-irradiated area. At five years, actuarial survival/relapse-free survival was 96.1/90% and 88.2/100% for ABVD and ABVD-Plt patients, respectively.
authors.affiliation: Service d'hématologie, hôpital de Beni-Messous, Cheraga, France.
authors.forename: M
authors.initials: M
authors.lastname: Belhani
authors.forename: M I
authors.initials: MI
authors.lastname: Belkaïd
authors.forename: R
authors.initials: R
authors.lastname: Ahmed-Naceur
authors.forename: M S
authors.initials: MS
authors.lastname: Abdiche
authors.forename: M
authors.initials: M
authors.lastname: Afiane
authors.forename: R
authors.initials: R
authors.lastname: Ghouadni
authors.forename: K
authors.initials: K
authors.lastname: Bouzid
authors.forename: F Z
authors.initials: FZ
authors.lastname: Ardjoun
authors.forename: J M
authors.initials: JM
authors.lastname: Andrieu
authors.forename: R M
authors.initials: RM
authors.lastname: Hamladji
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D013997:Time Factors
chemical_list: D002945:Cisplatin; D008775:Methylprednisolone
vernacular_title: Maladie de Hodgkin, stades cliniques IA-IIB: évaluation de l'intérêt du cisplatine. Résultats préliminaires.